DTYMK promote hepatocellular carcinoma proliferation by regulating cell cycle

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462.
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez A, Reig M, Bruix J. Treatment of hepatocellular carcinoma. Dig Dis. 2016;34(5):597–602.
   PubMed Web of Science ®Google Scholar
• Clark T, Maximin S, Meier J, et al. Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 2015;44(6):479–486.
   PubMed Web of Science ®Google Scholar
• Kim SK, Takeda H, Takai A, et al. Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis. J Gastroenterol. 2019;54(7):628–640.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Hoshida Y, Toffanin S, et al. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res. 2010;16(19):4688–4694.
   PubMed Web of Science ®Google Scholar
• Lee LS, Cheng Y. Human thymidylate kinase. Purification, characterization, and kinetic behavior of the thymidylate kinase derived from chronic myelocytic leukemia. J Biol Chem. 1977;252(16):5686–5691.
   PubMed Web of Science ®Google Scholar
• Huang SH, Tang A, Drisco B, et al. Human dTMP kinase: gene expression and enzymatic activity coinciding with cell cycle progression and cell growth. DNA Cell Biol. 1994;13(5):461–471.
   PubMed Web of Science ®Google Scholar
• Caspi R, Billington R, Fulcher CA, et al. The MetaCyc database of metabolic pathways and enzymes. Nucleic Acids Res. 2018;46(D1):D633–D639.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang X, Xu L, et al. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on the cancer genome atlas and gene expression omnibus datasets. Purinergic Signal. 2020;16(3):347–366.
   Web of Science ®Google Scholar
• Liu Y, Marks K, Cowley GS, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-Mutant lung cancer. Cancer Discov. 2013;3(8):870–879.
   PubMed Web of Science ®Google Scholar
• Yeh HW, Lee SS, Chang CY, et al. Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Oncotarget. 2017;8(44):77734–77751.
   PubMedGoogle Scholar
• Wang D, Liu J, Liu S, et al. Identification of crucial genes associated with immune cell infiltration in hepatocellular carcinoma by weighted gene Co-expression network analysis. Front Genet. 2020;11:342.
   PubMed Web of Science ®Google Scholar
• Lian Q, Wang S, Zhang G, et al. HCCDB: a database of hepatocellular carcinoma expression atlas. Genomics Proteomics Bioinformatics. 2018;16(4):269–275.
   PubMed Web of Science ®Google Scholar
• Menyhart O, Nagy A, Gyorffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5(12):181006.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Kaemmerer D, Peter L, Lupp A, et al. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5:187–194.
   PubMed Web of Science ®Google Scholar
• Min KW, CHAE SW, Kim D-H, et al. Fascin expression predicts an aggressive clinical course in patients with advanced breast cancer. Oncol Lett. 2015;10(1):121–130.
   PubMed Web of Science ®Google Scholar
• De Angelis PM, Fjell B, Kravik KL, et al. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. Int J Oncol. 2004;24:1279–1288.
   PubMed Web of Science ®Google Scholar
• Saxena P, Severi L, Santucci M, et al. Conformational propensity and biological studies of proline mutated LR peptides inhibiting human thymidylate synthase and ovarian cancer cell growth. J Med Chem. 2018;61(16):7374–7380.
   PubMed Web of Science ®Google Scholar
• Peters GJ, van der Wilt CL, van Triest B, et al. Thymidylate synthase and drug resistance. Eur J Cancer. 1995;31A(7–8):1299–1305.
   PubMed Web of Science ®Google Scholar
• Kim S, Park DH, Shim J. Thymidylate synthase and dihydropyrimidine dehydrogenase levels are associated with response to 5-fluorouracil in caenorhabditis elegans. Mol Cells. 2008;26:344–349.
   PubMed Web of Science ®Google Scholar
• Guo FY, Yang J, Xiong SM, et al. [Clinical significance of epidermal growth factor receptor and thymidylate synthase expression in primary liver cancer]. Zhonghua Gan Zang Bing Za Zhi. 2018;26:666–669.
   PubMedGoogle Scholar
• Peters GJ, van Triest B, Backus HHJ, et al. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer. 2000;36(7):916–924.
   PubMed Web of Science ®Google Scholar
• Mailand N, Gibbs-Seymour I, Bekker-Jensen S. Regulation of PCNA-protein interactions for genome stability. Nat Rev Mol Cell Biol. 2013;14(5):269–282.
   PubMed Web of Science ®Google Scholar
• Evison BJ, Actis ML, Wu SZ, et al. A site-selective, irreversible inhibitor of the DNA replication auxiliary factor proliferating cell nuclear antigen (PCNA). Bioorg Med Chem. 2014;22(22):6333–6343.
   PubMed Web of Science ®Google Scholar
• Moon J, Yu SJ, Kim HS, et al. Induction of G(1) cell cycle arrest and p27(KIP1) increase by panaxydol isolated from Panax ginseng. Biochem Pharmacol. 2000;59(9):1109–1116.
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348.
   PubMed Web of Science ®Google Scholar
• Wilson PM, Danenberg PV, Johnston PG, et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11(5):282–298.
   PubMed Web of Science ®Google Scholar
• Shiina T, Saito G, Sakaizawa T, et al. Higher tissue levels of thymidylate synthase determined by ELISA are associated with poor prognosis of patients with lung cancer. Tohoku J Exp Med. 2017;242(4):303–316.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Kaira K, Okubo Y, et al. Expression of thymidylate synthase (TS) and its prognostic significance in patients with cutaneous angiosarcoma. Neoplasma. 2017;64(6):916–921.
   PubMed Web of Science ®Google Scholar
• Hu CM, Chang ZF. Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status. Cancer Res. 2008;68(8):2831–2840.
   PubMed Web of Science ®Google Scholar
• Hu CM, Chang ZF. Mitotic control of dTTP pool: a necessity or coincidence? J Biomed Sci. 2007;14(4):491–497.
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhang Y, Sun J, et al. Raltitrexed inhibits HepG2 cell proliferation via G0/G1 cell cycle arrest. Oncol Res. 2016;23(5):237–248.
   PubMed Web of Science ®Google Scholar